Skip to content

Effects of Xue Zhi Kang on acute kidney and mechanism study

Effects of Xue Zhi Kang on acute kidney and mechanism study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17012464
Enrollment
Unknown
Registered
2017-08-24
Start date
2017-09-01
Completion date
Unknown
Last updated
2017-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute kidney

Interventions

Xue Zhi Kang Group:Xue Zhi Kang
CONTROL:None, without statin

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Type 2 DM; 2. CKD2-3; 3. contrast medium volume?100ml; 4. Aged 18-80 years; 5. signed written consent inform; 6. not received any statin treatment for at least 14 days; 7. metformin or aminophylline had been withdrawn for at least 2 days prior to contrast medium administration.

Exclusion criteria

Exclusion criteria: 1. Pregnancy; 2. type 1 DM, ketoacidosis, lactic acidosis; 3. hypersensitivity to contrast medium or statins; 4. administration of iodinated contrast medium during the 2 weeks before randomization; 5. need to undergo emergency CAG; 6. Cardiac shockClass III- IV heart failure; 7. Serious hepatic and renal dysfunction; 8. Late malignant tumor,acute gastrointestinal bleeding, acute stroke, Mental illness, etc; 9. administration of Aminophylline/theophylline within 7 days; 10. attending other study.

Design outcomes

Primary

MeasureTime frame
serum creatine;

Secondary

MeasureTime frame
NGAL;renalase;

Countries

China

Contacts

Public ContactZHAO QING

Shanghai Sixth People's Hospital

zhaoqing2@medmail.com.cn+86 18930174137

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026